Cetuximab
Based on 55 publication(s) in Google Scholar
Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.81%
- CAS. Nr.: 205923-56-4
- Molecular Weight:145.54 kDa
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Cetuximab
More- Cell. 2023 Dec 7;186(25):5606-5619.e24. [Abstract]
- Mol Cancer. 2021 Jan 18;20(1):17. [Abstract]
- Nat Nanotechnol. 2025 Feb;20(2):296-302. [Abstract]
- Cell Res. 2023 Jan;33(1):30-45. [Abstract]
- Cell Res. 2020 Dec;30(12):1063-1077. [Abstract]
- Adv Mater. 2025 Aug;37(32):e2504050. [Abstract]
- Cancer Commun (Lond). 2025 Dec 25.
- Nat Cancer. 2026 Jan;7(1):116-130. [Abstract]
- Cell Stem Cell. 2025 Jul 3;32(7):1087-1101.e4. [Abstract]
- Cancer Res. 2025 Dec 18. [Abstract]
- Cancer Res. 2025 Jun 10:10.1158/0008-5472.CAN-24-3904. [Abstract]
- Am J Respir Crit Care Med. 2022 Dec 1;206(11):1336-1352. [Abstract]
- Nat Commun. 2024 Jul 12;15(1):5874. [Abstract]
- Nat Commun. 2022 Feb 1;13(1):594. [Abstract]
- Theranostics. 2024 Aug 26;14(14):5443-5460. [Abstract]
- Theranostics. 2020 Apr 6;10(11):5107-5119. [Abstract]
- J Clin Invest. 2024 Oct 22;134(24):e182217. [Abstract]
- Adv Sci (Weinh). 2025 Mar;12(12):e2408845. [Abstract]
- Cell Rep Med. 2025 Jul 15;6(7):102195. [Abstract]
- Med. 2023 Jul 14;4(7):457-477.e8. [Abstract]
- J Transl Int Med. 2026 Mar 26;14(2):237-258. [Abstract]
- J Control Release. 2024 Nov:375:643-653. [Abstract]
- EBioMedicine. 2023 Mar:89:104451. [Abstract]
- Genome Med. 2021 Apr 14;13(1):58. [Abstract]
- Oncogene. 2026 Jun;45(22):2137-2154. [Abstract]
- Chin Med J (Engl). 2025 Aug 5;138(15):1853-1865. [Abstract]
- Oncogene. 2021 Apr;40(14):2581-2595. [Abstract]
- Int J Biol Macromol. 2025 Oct 13:148268. [Abstract]
- Int J Biol Macromol. 2025 Feb 17;305(Pt 2):141153. [Abstract]
- EMBO Mol Med. 2025 Dec;17(12):3525-3554. [Abstract]
- Biosensors (Basel). 2023 Mar 14;13(3):383. [Abstract]
- J Cell Biol. 2021 Nov 1;220(11):e202107103. [Abstract]
- Int J Pharm. 2024 Jul 20:660:124262. [Abstract]
- Biomacromolecules. 2023 Jul 10;24(7):3228-3236. [Abstract]
- Cell Rep Methods. 2026 Jun 15;6(6):101416. [Abstract]
- Commun Biol. 2024 Dec 31;7(1):1719. [Abstract]
- Cell Rep Methods. 2023 Aug 15;3(8):100560. [Abstract]
- J Gastroenterol. 2025 May 25. [Abstract]
- Int J Mol Sci. 2025 Apr 22;26(9):3941. [Abstract]
- Int J Mol Sci. 2022 Aug 6;23(15):8754. [Abstract]
- Mol Med Rep. 2026 Feb;33(2):77. [Abstract]
- Sci Rep. 2022 Jul 7;12(1):11561. [Abstract]
- Cancers (Basel). 2024 Nov 5;16(22):3732. [Abstract]
- J Cell Mol Med. 2020 Jul;24(13):7313-7330. [Abstract]
- iScience. 2024 Mar 7;27(4):109450. [Abstract]
- BMC Cancer. 2023 Jul 12;23(1):652. [Abstract]
- Bioorg Med Chem. 2023 Jan 15:78:117114. [Abstract]
- J Biomed Opt. 2025 Dec;30(12):126002. [Abstract]
- bioRxiv. 2025 Mar 2:2025.02.26.640419. [Abstract]
- Precision Medicine and Engineering. 2024 Dec.
- Patent. US20230340070A1.
- bioRxiv. 2023 Jun 29.
- ABO Akademi University. 2023 May.
- Visualizing and Quantifying Drug Distribution in Tissue V. 116240F (2021).
- bioRxiv. 2020 Jun.
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
WB
-
Cell Proliferation/Viability Assay
-
WB
-
IHC
Alle Radionuclide-Drug Conjugates (RDCs) Isoform-spezifische Produkte anzeigen
MoreAlle EGFR Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Human IgG1 kappa
Human
|
EGFR 0.147 nM (Kd, Fixed A431 cells) |
RDC Antibody |
Soluble EGFR 0.201 nM (Kd) |
Cetuximab (C225) is a monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for soluble EGFR by SPR. Cetuximab also exhibits a Kd of 0.147 nM for EGFR in fixed A431 cells by ELISA[1].
Cetuximab (C225; 30 nM) time-dependently inhibits the proliferation of SCC-1, SCC-11B, SCC-38, and SCC-13Y cells after treatment for 8 d. Cetuximab (30 nM) causes G0/G1 arrest, induces apoptosis, and reduces Rb, p27KIP1, Bcl-2, and Bax expression in SCC-13Y cells. Cetuximab (30 nM) also enhances radiosensitivity and increases radiation-induced apoptosis in SCC-13Y cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Cetuximab has a significant ADCC effect on A431 cells in a dose-dependent manner.The EC50 for this effect is 43.50 and 39.11 ng/mL.
Chemical Information
-
CAS. Nr. 205923-56-4
-
Appearance Liquid
-
Molecular Weight 145.54 kDa
-
Color Colorless to light yellow
-
SMILES
[Cetuximab]
-
Synonyms
C225; IMC-C225
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (55)
-
Journal Impact Factor
-
Most Recent
-
Cell
Trellis tree-based analysis reveals stromal regulation of patient-derived organoid drug responses. [Abstract]2023 Dec 7;186(25):5606-5619.e24. PMID: 38065081 -
Mol Cancer
Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer. [Abstract]2021 Jan 18;20(1):17. PMID: 33461557 -
Nat Nanotechnol
2025 Feb;20(2):296-302. PMID: 39468359 -
Cell Res
A novel protein RASON encoded by a lncRNA controls oncogenic RAS signaling in KRAS mutant cancers. [Abstract]2023 Jan;33(1):30-45. PMID: 36241718 -
Cell Res
Myofiber necroptosis promotes muscle stem cell proliferation via releasing Tenascin-C during regeneration. [Abstract]2020 Dec;30(12):1063-1077. PMID: 32839552 -
Adv Mater
Highly Specific Cytokine Receptor-Targeting Chimeras for Targeted Membrane Protein Degradation and Sensitization of Osimertinib in EGFR-Mutated Non-Small-Cell Lung Cancer. [Abstract]2025 Aug;37(32):e2504050. PMID: 40401615 -
-
Nat Cancer
The MEK-RAF molecular glue IK-595 has potent antitumor activity across RAS/MAPK pathway-altered cancers. [Abstract]2026 Jan;7(1):116-130. PMID: 41482524 -
Cell Stem Cell
Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy. [Abstract]2025 Jul 3;32(7):1087-1101.e4. PMID: 40472844 -
Cancer Res
Oncolytic HSV-1-Mediated JAG1 Blockade Induces Glioma Senescence-Associated Secretory Phenotype to Increase Macrophage Activation and Cetuximab-Mediated Senolysis. [Abstract]2025 Dec 18. PMID: 41411618 -
Cancer Res
NF1 Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in NF1 Mutant Melanoma. [Abstract]2025 Jun 10:10.1158/0008-5472.CAN-24-3904. PMID: 40494652 -
Am J Respir Crit Care Med
2022 Dec 1;206(11):1336-1352. PMID: 35816430 -
Nat Commun
Therapeutic potential of the secreted Kazal-type serine protease inhibitor SPINK4 in colitis. [Abstract]2024 Jul 12;15(1):5874. PMID: 38997284 -
Nat Commun
2022 Feb 1;13(1):594. PMID: 35105871
Cetuximab purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Feb 1;13(1):594. [Abstract]
Cetuximab (1.5 mg/kg; i.p.; single dose). Quantitative analysis of P-EGFR in tumor sections observed by western blot analysis
Cetuximab purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Feb 1;13(1):594. [Abstract]
Cetuximab (1.5 mg/kg; i.p.; single dose). Quantitative analysis of P-EGFR in tumor sections observed by IHC analysis.
-
Theranostics
Honokiol enhances the sensitivity of cetuximab in KRASG13D mutant colorectal cancer through destroying SNX3-retromer complex. [Abstract]2024 Aug 26;14(14):5443-5460. PMID: 39310106
Cetuximab purchased from MedChemExpress. Usage Cited in: Theranostics. 2024 Aug 26;14(14):5443-5460. [Abstract]
Cell viability by administrating various concentrations of cetuximab (Cmab) (20-160 μg/mL) and 25 μM HNK in HCT116 and LoVo cells.
-
Theranostics
Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation. [Abstract]2020 Apr 6;10(11):5107-5119. PMID: 32308771
Cetuximab purchased from MedChemExpress. Usage Cited in: Theranostics. 2020 Apr 6;10(11):5107-5119. [Abstract]
The effect of cetuximab and β-elemene in combination (25 μg/mL) with other cell death inhibitors on the cell viability of KRAS mutant HCT116 and Lovo cells after the treatment for 24 h.
Cetuximab purchased from MedChemExpress. Usage Cited in: Theranostics. 2020 Apr 6;10(11):5107-5119. [Abstract]
The expression of positive regulatory proteins for ferroptosis (HO-1 and transferrin) and the negative regulatory proteins for ferroptosis (GPX4, SLC7A11, FTH1, glutaminase, and SLC40A1) were detected by western blotting after the treatment (β-elemene 125 µg/mL, cetuximab 25 µg/mL) for 24 h.
-
J Clin Invest
MOGAT3-Mediated DAG Accumulation Drives Acquired Resistance to Anti-BRAF/EGFR Therapy in BRAFV600E-Mutant Metastatic Colorectal Cancer. [Abstract]2024 Oct 22;134(24):e182217. PMID: 39436710
Cetuximab purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2024 Oct 22;134(24):e182217. [Abstract]
Top: Western blots showing protein expression of MOGAT3 in RKO, RKO EC-R, HT29, and HT29 EC-R cells. Representative blots are shown. MOGAT3KO RKO EC-R and HT29 EC-R, along with RKO EC-R-CTRL and HT29 EC-R-CTRL cell lines, were exposed to 2 μM encorafenib/4 μM cetuximab for 96 hours. Bottom: Relative OD value was assessed to determine cell viability by the CCK-8 assay (n = 3).
-
Adv Sci (Weinh)
2025 Mar;12(12):e2408845. PMID: 39888307 -
Cell Rep Med
iPSC-derived trimodal T cells engineered with CAR, TCR, and hnCD16 modalities can overcome antigen escape in heterogeneous tumors. [Abstract]2025 Jul 15;6(7):102195. PMID: 40541190 -
Med
A chimeric antigen receptor uniquely recognizing MICA/B stress proteins provides an effective approach to target solid tumors. [Abstract]2023 Jul 14;4(7):457-477.e8. PMID: 37172578 -
J Transl Int Med
Anti-SIA-cIgG enhances chemotherapy effectiveness through PTPN13-regulated tumor stemness in head and neck squamous cell carcinoma. [Abstract]2026 Mar 26;14(2):237-258. PMID: 42046805 -
J Control Release
Confined copper depletion via a hydrogel platform for reversing dabrafenib/cetuximab resistance in BRAFV600E-mutant colorectal cancer. [Abstract]2024 Nov:375:643-653. PMID: 39306044
Cetuximab purchased from MedChemExpress. Usage Cited in: J Control Release. 2024 Nov:375:643-653. [Abstract]
Cell viability of RKO cells after treated by different concentrations of dabrafenib and cetuximab. The concentration gradient of dabrafenib and cetuximab varied from 0.39 to 50 μg/mL.
-
EBioMedicine
VPS35 promotes cell proliferation via EGFR recycling and enhances EGFR inhibitors response in gastric cancer. [Abstract]2023 Mar:89:104451. PMID: 36738481 -
Genome Med
PRMT1-mediated H4R3me2a recruits SMARCA4 to promote colorectal cancer progression by enhancing EGFR signaling. [Abstract]2021 Apr 14;13(1):58. PMID: 33853662 -
Oncogene
MTPN drives noncanonical ERK hyperactivation in colorectal cancer and provides a promising therapeutic approach for precision medicine in CRC. [Abstract]2026 Jun;45(22):2137-2154. PMID: 42009970 -
Chin Med J (Engl)
Precision therapy targeting CAMK2 to overcome resistance to EGFR inhibitors in FAT1-mutated oral squamous cell carcinoma. [Abstract]2025 Aug 5;138(15):1853-1865. PMID: 39227322 -
Oncogene
LIMK1 nuclear translocation promotes hepatocellular carcinoma progression by increasing p-ERK nuclear shuttling and by activating c-Myc signalling upon EGF stimulation. [Abstract]2021 Apr;40(14):2581-2595. PMID: 33686242 -
Int J Biol Macromol
Brain abundant membrane attached signal protein 1 regulates macrophage polarization through EGFR/PI3K/AKT signaling in renal cell carcinoma. [Abstract]2025 Oct 13:148268. PMID: 41093214 -
Int J Biol Macromol
UVA-responsive Fe₃O₄@ZnO nanocarrier grafted with anti-EGFR antibody for precision delivery of Nrf2-siRNA and brusatol: A novel platform for integrated photodynamic, gene, and chemotherapy. [Abstract]2025 Feb 17;305(Pt 2):141153. PMID: 39971059 -
EMBO Mol Med
circ-EGFR is a predictor of response to Cetuximab and a potential target in colorectal cancer. [Abstract]2025 Dec;17(12):3525-3554. PMID: 41214390 -
Biosensors (Basel)
2023 Mar 14;13(3):383. PMID: 36979595 -
J Cell Biol
EGFR-RAS-MAPK signaling is confined to the plasma membrane and associated endorecycling protrusions. [Abstract]2021 Nov 1;220(11):e202107103. PMID: 34515735 -
Int J Pharm
Exosome-mediated delivery platform of biomacromolecules into the brain: Cetuximab in combination with doxorubicin for glioblastoma therapy. [Abstract]2024 Jul 20:660:124262. PMID: 38815637 -
Biomacromolecules
2023 Jul 10;24(7):3228-3236. PMID: 37319440 -
Cell Rep Methods
Efficiency landscape of bioorthogonal click reactions producing bispecific antibody conjugates. [Abstract]2026 Jun 15;6(6):101416. PMID: 42019503 -
Commun Biol
Proteolysis targeting chimera (PROTAC)-driven antibody internalization of oncogenic cell surface receptors. [Abstract]2024 Dec 31;7(1):1719. PMID: 39741170 -
Cell Rep Methods
2023 Aug 15;3(8):100560. PMID: 37671023 -
J Gastroenterol
SEC61G promotes colorectal cancer progression by regulating cytosolic Ca2+ concentration. [Abstract]2025 May 25. PMID: 40413702 -
Int J Mol Sci
Dual Disruption of EGFR/PI3K Signaling: IGF2BP2 Targeting Reverses Anti-EGFR Resistance in CAFs-Infiltrated Oral Squamous Cell Carcinoma. [Abstract]2025 Apr 22;26(9):3941. PMID: 40362183 -
Int J Mol Sci
A Multiscale Molecular Dynamic Analysis Reveals the Effect of Sialylation on EGFR Clustering in a CRISPR/Cas9-Derived Model. [Abstract]2022 Aug 6;23(15):8754. PMID: 35955894 -
Mol Med Rep
ISX promotes tumor migration and invasion in lung cancer by upregulating COL1A1 in vitro. [Abstract]2026 Feb;33(2):77. PMID: 41480691 -
Sci Rep
Synchronous intracellular delivery of EGFR-targeted antibody-drug conjugates by p38-mediated non-canonical endocytosis. [Abstract]2022 Jul 7;12(1):11561. PMID: 35798841 -
Cancers (Basel)
Targeting the EGFR and Spindle Assembly Checkpoint Pathways in Oral Cancer: A Plausible Alliance to Enhance Cell Death. [Abstract]2024 Nov 5;16(22):3732. PMID: 39594688 -
J Cell Mol Med
Epidermal growth factor regulates the development of stem and progenitor Leydig cells in rats. [Abstract]2020 Jul;24(13):7313-7330. PMID: 32441057 -
iScience
Phenotypic switching as a non-genetic mechanism of resistance predicts antibody therapy regimens. [Abstract]2024 Mar 7;27(4):109450. PMID: 38544569 -
BMC Cancer
RUNX3 regulates the susceptibility against EGFR-targeted non-small cell lung cancer therapy using 47Sc-conjugated cetuximab. [Abstract]2023 Jul 12;23(1):652. PMID: 37438719 -
Bioorg Med Chem
2023 Jan 15:78:117114. PMID: 36563514 -
J Biomed Opt
Epidermal growth factor receptor-targeted near-infrared probe cetuximab-IRDye800CW enables stable and tumor-specific fluorescence imaging in colorectal cancer models. [Abstract]2025 Dec;30(12):126002. PMID: 41346398 -
bioRxiv
Enhanced fluorescence lifetime imaging microscopy denoising via principal component analysis. [Abstract]2025 Mar 2:2025.02.26.640419. PMID: 40060483 -
-
-
-
-
-
Reinheit & Dokumentation
-
Data Sheet (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
[1]. Goldstein NI, et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res. 1995 Nov;1(11):1311-8. [Content Brief]
[2]. Gustafsson H, et al. EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model. Cell Biochem Biophys. 2017 Jul 29. [Content Brief]
[3]. Huang SM, et al. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999 Apr 15;59(8):1935-40. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Cetuximab Related Classifications
HY-P9905 Related Classifications
Powered by Bioz